GlassScriptPhysician profile
Scott David Hurley
NPI 1326380247
$4,798.09
in general payments reported to CMS, 2019-2025
29 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.66 · 2020: $49.72 · 2021: $1,724 · 2022: $871 · 2023: $796 · 2024: $849 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081 · Education: $41.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.56 |
| Education | $41.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,280.11 | 2020-2025 | Amplatzer Amulet, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $516.90 | 2020-2025 | |
| Boston Scientific Corporation | $479.94 | 2021-2025 | Watchman Access System, Watchman Flx |
| Merck Sharp & Dohme LLC | $231.62 | 2022-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.68 | 2022-2025 | Lifevest |
| Heartflow, INC. | $176.55 | 2024-2025 | |
| Pfizer INC. | $131.89 | 2022-2025 | |
| Amgen INC. | $88.92 | 2022-2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $77.30 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $56.07 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Lantheus Medical Imaging, INC. | $55.58 | 2023-2024 | Definity |
| Bayer Healthcare Pharmaceuticals INC. | $50.93 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.38 | 2022-2023 | Farxiga, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.48 | 2019-2023 | Jardiance |
| Bridgebio Pharma, INC. | $41.78 | 2025 | Attruby |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $32.69 | 2022-2024 | Intellis Adaptivestim |
| United Therapeutics Corporation | $31.40 | 2024 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $31.05 | 2025 | Onpattro |
| Scpharmaceuticals INC. | $30.30 | 2024-2025 | |
| Chiesi USA, INC. | $28.89 | 2023 | Kengreal, Cleviprex |
| Novo Nordisk INC | $23.13 | 2023 | Ozempic |
| Ge Healthcare | $22.32 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $22.30 | 2025 | Evkeeza |
| Cvrx, INC. | $20.38 | 2024 | Barostim Neo System |
| Medicomp INC | $19.76 | 2023 | Telepatch Cardiac Monitor |
| Zoll Circulation INC | $18.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.48 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.